Why you can't quit the thing you meant to quit — what biology contributes

The willpower explanation is not only unhelpful. It is, at the level of neuroscience, substantially inaccurate.

What drives compulsive behavior and substance use is a specific cluster of neurobiological changes centered on the dopaminergic reward circuit. Dopamine is the brain's primary learning and anticipation signal. It fires in response to rewards and, critically, to the cues that predict rewards — and it calibrates behavior toward the things that reliably produce dopamine release. In a healthy reward circuit, dopamine releases in proportion to the unexpected reward, and the signal fades as the behavior becomes routine. The problem with highly reinforcing substances and behaviors is that they hijack this system: alcohol, sugar, nicotine, and certain behavioral patterns like compulsive screen use produce dopamine releases larger and faster than anything the evolved brain was calibrated for. Over time, the reward circuit compensates by downregulating dopamine receptors and baseline dopamine tone — a form of tolerance that means the behavior that once produced pleasure now produces something closer to relief from the deficit it created. Stopping feels aversive not because of moral failure but because the circuit has recalibrated around the substance or behavior, and its absence registers as a genuine neurological shortage.

The prefrontal cortex is the other half of this. The prefrontal cortex is responsible for impulse regulation, future-oriented decision-making, and the override of immediate reward in favor of longer-term goals. It is the system that says "you decided not to do this" and routes behavior accordingly. It requires adequate neurotransmitter function, adequate sleep, low inflammatory load, and low acute stress to work at full capacity. Chronic stress, sleep deprivation, high cortisol, and the very dysregulation that often leads people to lean on substances in the first place all impair prefrontal function. This creates a vicious architecture: the behaviors that people are trying to stop are often, in part, regulatory strategies for stress or anxiety — and the stress and anxiety that drive them simultaneously compromise the prefrontal capacity that would allow override. Willpower lives in the prefrontal cortex. Telling someone to use more willpower in a state of chronic stress and sleep deprivation is physiologically analogous to telling someone to run faster on a broken leg.

The HPA stress axis adds a third layer. The hypothalamic-pituitary-adrenal axis governs the stress response, and it is tightly linked to the reward circuit through shared neuroanatomy and shared signaling molecules. Chronic stress — whether from work, relationships, chronic pain, financial pressure, or any other sustained demand — keeps cortisol elevated and dysregulates the dopamine system in ways that amplify craving. Stress is one of the most reliable triggers for relapse in people recovering from substance use disorders, and it's one of the most reliable triggers for abandoning dietary or behavioral change in people who don't meet clinical criteria for addiction. The neurobiology is the same. The scale is different.

Specific neurotransmitter deficits contribute differently depending on the substance and the person. GABA insufficiency — common in people with anxiety — creates the template for alcohol's effectiveness as a regulatory strategy: alcohol potentiates GABA, producing a reduction in the arousal and anxiety that was driving the behavior. The person isn't drinking because they lack discipline; they're drinking because the alcohol is producing a neurochemical correction that their brain is genuinely seeking. The same logic applies to nicotine and acetylcholine pathways, to sugar and opioid receptor activation in the reward circuit, to social media's exploitation of variable-ratio reinforcement schedules — the same mechanism as a slot machine. In every case, the behavior is producing a neurological effect that the brain has learned to seek, and the seeking is not voluntary in the way the willpower model assumes.

The microbiome connection is underappreciated and real. The gut microbiome communicates with the brain through the vagus nerve and through the production of neurotransmitter precursors including serotonin — roughly 90 percent of which is produced in the gut — GABA, and other signaling molecules. Microbiome composition affects mood, anxiety level, and craving in ways that are still being characterized. Dysbiosis in the gut microbiome is associated with altered reward processing and increased stress reactivity. For people whose compulsive behavior involves sugar or food specifically, the microbiome connection is particularly relevant: certain bacterial communities promote sugar craving through direct signaling pathways. This is not a fringe finding. It's an emerging and reasonably well-supported area of the literature.

The GLP-1 story in addiction is one of the most interesting developments in this space in the last several years. GLP-1 — glucagon-like peptide 1 — is an incretin hormone produced in the gut and also in the brainstem. It acts on GLP-1 receptors distributed throughout the brain, including in the ventral tegmental area and nucleus accumbens — the core structures of the dopaminergic reward circuit. The observation that GLP-1 agonists reduce not only appetite but also alcohol craving and consumption in many users was initially a clinical surprise; it has since prompted a significant body of research on GLP-1's role in reward processing more broadly. Studies have found reductions in alcohol consumption, reports of reduced craving across multiple substance categories, and emerging signals for effects on compulsive behaviors. The mechanism appears to involve GLP-1's modulation of dopamine signaling in reward circuitry — essentially reducing the anticipatory signal that drives seeking behavior. This does not mean GLP-1 agonists are appropriate for every person trying to reduce a habit; the clinical context, the severity of the behavior, and the appropriate workup all matter and are conversations for your prescribing provider.

For clinical addiction — alcohol use disorder, substance use disorder, behavioral addictions meeting diagnostic criteria — the professional treatment framework matters more than any single pharmacological intervention. Medication-assisted treatment for alcohol use disorder (naltrexone, acamprosate, disulfiram) has substantial evidence. Buprenorphine for opioid use disorder has transformed treatment outcomes in that population. The broader addiction medicine framework, including behavioral therapies and recovery support, addresses the psychological, social, and environmental dimensions that pharmacology alone doesn't reach. The most important intervention for clinical addiction is professional treatment, not optimization. This is not a semantic distinction.

For the sub-clinical pattern — the person who drinks more than they'd like, can't stop the sugar, keeps returning to the screen, hasn't met diagnostic criteria for any disorder but is genuinely frustrated with their inability to change behavior they've decided to change — the biology still matters. Environmental restructuring does more than willpower: removing the trigger eliminates the need for override, which is neurologically much more reliable than expecting the prefrontal cortex to succeed in the presence of cues that activate the reward circuit. Addressing the underlying anxiety or depression that the behavior is often regulating — through whatever combination of professional support, medication, and lifestyle intervention is appropriate — removes the neurological demand that's driving the behavior in the first place. Treating sleep deprivation as the prefrontal impairment it actually is changes the equation. These are not willpower substitutes. They're interventions in the actual mechanism.

The "can't quit" pattern is a biological signal, not a character assessment. The reward circuit and the prefrontal cortex are doing exactly what they do in a nervous system under this kind of repeated, reinforcing exposure. That the brain can change in both directions — can be recalibrated through sustained behavioral and environmental change, and sometimes through specific pharmacological support — is the basis for realistic optimism. But the recalibration requires working with the biology, not against it. And it begins with retiring the framing that makes neurobiology a matter of willpower.